Prospects of using Antagonist Histamine H2-Receptor (Cimetidinum) as Adjuvant for Melanoma Biotherapy Treatment

TL;DR

This study investigates the potential of Cimetidine, an H2 receptor antagonist, as an adjuvant to enhance melanoma vaccine efficacy in mice, showing increased preventive effects and prolonged survival in some cases.

Contribution

It demonstrates that Cimetidine can improve melanoma vaccine outcomes and suggests further research into its use as an adjuvant in melanoma immunotherapy.

Findings

Cimetidine increased preventive effects of melanoma vaccination.

33% of mice showed no tumor growth within 60 days.

Cimetidine monotherapy tended to increase lifespan and reduce metastasis.

Abstract

Improvement of anti-tumor biotherapy effectiveness by modification of immune response with histamine H2 receptor Cimetidinum (CM) was studied using the experimental murine model of B16 F10 melanoma in vivo. It is shown that skin melanoma biotherapy by antitumor whole-cell GM-CSF-producing vaccine with the addition of CM (in dose of 25 mg/kg, daily for 5 days) increases preventive effects of vaccination. 33 % of mice did not have tumor growth within 60 days of observation. Average life span of animals exceeded those of the control group up to 68 %. Using CM-combined bio-chemotherapy doesn't improve therapeutic effect, however in the case of a monotherapeutic approach tendency for increased average life-time and decreased metastatic processes in mice with the developed tumors was noticed. Aquired data provides expediency to study the further application of CM as adjuvant for skin melanoma vaccinotherapy, and also the necessity to verify the immune status of an organism against the complex bio-chemotherapy.